NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development.
Deal Flow
Fundings
| Closing Date | Round | Amount |
|---|---|---|
| 07/01/2004 | Unattributed | $40,000,000 |
| 05/01/2000 | Unattributed | $2,000,000 |
| 04/01/2000 | Unattributed | $46,800,000 |
Mergers & Acquisitions
Public Offerings
| Closing Date | Shares | Amount |
|---|---|---|
| 09/01/2005 | 7,000,000 | $79,500,000 |
| 06/01/2003 | $192,000,000 | |
| 10/01/2002 | 4,600,000 | $110,170,000 |
| 11/01/2000 | 4,600,000 | $193,200,000 |
Company Snapshot
No
Biotechnology | Pharmaceutical
Acquired
Public
$84,150,000
$88,600,000
1
47
Founded in Utah in 1983. Merged with Bridgewater in 2003. Now headquatered in New Jersey
Key People
-
Luke M. Beshar
CFO
-
Alan G. Harris
SVP and Chief Medical Officer
-
Andrew Rackear
SVP and JD
-
Douglas N. Dobak
VP of Regulatory Affairs and Drug Safety and MBA
-
Francois Nader
CEO and President






